Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumour cells.
U.S. study compares 81 mg vs 325 mg ASA to lower cardiovascular risk and mortality in patients with established atherosclerotic cardiovascular disease.